OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Treatment Reviews is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon	188
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer	179
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	170
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer	161
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis	141
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms	127
Acknowledgement to Reviewers 2021	120
Editorial Board	117
Editorial Board	105
Editorial Board	103
Editorial Board	101
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review	86
Editorial Board	81
Editorial Board	80
Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)	76
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations	74
The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review	73
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review	70
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications	69
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	65
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis	60
Editorial Board	60
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma	59
The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review	57
PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives	57

Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches	55
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies	53
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines	52
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis	51
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias	51
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?	51
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions	49
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	49
Current state of play for HPV-positive oropharyngeal cancers	48
NTRK gene fusion testing and management in lung cancer	48
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers	45
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review	45
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	45
Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis	45
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice	44
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy	43
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma	42
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants	42
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon	42